Neumora has $85.7M cash, needs substantial funding
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Neumora Therapeutics, Inc. (NMRA) reported third-quarter 2026 results and pipeline updates, including submission of an Investigational New Drug application for NMRA-215 to the U.S. Food and Drug Administration. Net loss was $34.4 million, compared with $56.8 million in the third quarter of 2025. Research and development expense was $22.6 million versus $40.5 million, and general and administrative expense was $10.8 million versus $12.2 million. Cash and cash equivalents were $85.7 million as of September 30, 2026, compared with $182.5 million as of December 31, 2025. Neumora said substantial additional funding will be required to continue operations and complete development and, if approved, commercialization of its candidates; it said there is no assurance funding will be available or on what terms, and provided no updated financial runway guidance.
Preclinical diet-induced-obesity mouse studies of NMRA-215 reported weight loss of up to 19% as monotherapy and up to 26% with semaglutide. In a multiple ascending dose expansion cohort, 30 mg twice daily of NMRA-511 in healthy elderly participants had a favorable safety and tolerability profile, no serious adverse events, and dose-proportional increases in exposure compared with 20 mg twice daily evaluated in a Phase 1b study. Neumora said NMRA-511 is Phase 2 enabled. A Phase 1 multiple ascending dose study of NMRA-898 is ongoing in healthy volunteers and patients with stable schizophrenia.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointThird-quarter net loss fell to $34.4 million from $56.8 million.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.September 30 cash was $85.7 million; Neumora says substantial additional funding is required.
8-K Event Classification
Key Figures
Key Terms
Investigational New Drug (IND) application regulatory
NLRP3 inhibitor medical
multiple ascending dose (MAD) medical
dose-proportional increase in exposure technical
positive allosteric modulator medical
diet-induced obesity (DIO) medical
Earnings Snapshot
Neumora is not providing updated financial runway guidance. It said substantial additional funding will be required to continue operations and complete development and, if approved, commercialization of its product candidates, and that there can be no assurance such funding will be available or on what terms.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was NMRA's net loss in the third quarter of 2026?
What did NMRA report for its NMRA-215 obesity program?
What were the NMRA-511 multiple ascending dose results?
AI-generated analysis. How Rhea-AI works. Not financial advice.
